Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.

ABSTRACT: Medulloblastoma is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most patients with medulloblastoma receive similar therapies, including surgery, radiation, and intensive chemotherapy. Although these treatments prolong survival, many patients still die from the disease and survivors suffer severe long-term side effects from therapy. We hypothesize that each patient with medulloblastoma is sensitive to different therapies and that tailoring therapy based on the molecular and cellular characteristics of patients' tumors will improve outcomes. To test this, we assembled a panel of orthotopic patient-derived xenogr

SUBMITTER: Rusert JM 

PROVIDER: S-EPMC7718387 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature